Cara Therapeutics (CARA) Debt/EBITDA US GAAP (year values)

2020 2021 2022 2023 2023   LTM ? CAGR 5 years ?
Debt/EBITDA -31.4 1.85 1.71 0.47 0.49   0.09  
Changes by years, y/y, % -2 423% -106% -8% -72% +3%     -25.2%

Cara Therapeutics. Debt/EBITDA

Cara Therapeutics. Debt/EBITDA, changes, %

Cara Therapeutics (CARA) Debt/EBITDA US GAAP (quarter values)

2023Q3 2023Q4 2023Q4 2024Q1 2024Q2   LTM ?
Debt/EBITDA 0.60 0.48 0.49 0.20 0.09   0.09
Changes by years, y/y, % -65% -71% -70% -84% -89%    
Changes by quarters, q/q, % -27% -20% +2% -58% -56%    

Cara Therapeutics. Debt/EBITDA

Cara Therapeutics. Debt/EBITDA, changes, y/y, %

Cara Therapeutics. Debt/EBITDA, changes, q/q, %